Bristol-Myers Squibb holds key support, shares lag broader pharma peers
25.06.2026 - 16:06:47 | ad-hoc-news.de
By Daniel Hoffmann, Chart & Technicals desk. Reviewed prior to publication on 2026-06-25, 16:06.
Bristol-Myers Squibb (US1078421011) trades on the NYSE with the shares hovering in the mid-50 dollar range this week. The focus for traders on Thursday is on the current chart picture and how the BMY line compares with other large-cap pharmaceutical names such as Pfizer and Merck.
What recent price data shows
Data from MarketBeat puts the previous regular-session close for Bristol-Myers Squibb shares at 55.14 dollars on 2026-06-24, with an intraday high of 56.59 dollars and a low of 54.78 dollars.MarketBeat overview for BMY That range underlines a still active trading band of roughly 2 dollars around the 55 dollar mark.
The same overview shows a 50-day trading range between approximately 54.10 and 56.59 dollars for the BMY shares, indicating that the stock has spent recent weeks consolidating without breaking out of this corridor.MarketBeat key stats for Bristol-Myers Squibb For chart observers, that band acts as a near-term support and resistance zone.
Sector context and peer comparison
Bristol-Myers Squibb operates in the large-cap biopharmaceutical space, where US peers like Pfizer, Merck and Eli Lilly help define sentiment for the wider group. On many market-data pages, BMY is classified in the medical sector with a focus on biomedicine and gene-related pharmaceuticals, making it part of the broader defensive healthcare complex.MarketBeat sector and industry data for BMY This sector reference is important when investors compare valuation and momentum.
Analyst consensus figures compiled by Pandaforecast cite a current value of about 55 dollars for Bristol-Myers Squibb and an average analyst price expectation around 63.08 dollars, suggesting a moderate upside profile relative to present trading levels.Pandaforecast summary on BMY While those are not investment guarantees, they give retail investors a documented sense of how research houses stack up the stock against its peers.
All news and analysis on the Bristol-Myers Squibb shares
Further articles, key figures and regulatory disclosures on the Bristol-Myers Squibb equity can be found in the dedicated topic section.
The products behind the stock
Bristol-Myers Squibb generates most of its revenue with prescription medicines in oncology, cardiovascular and immunology. A flagship product from the current portfolio is the cancer immunotherapy Opdivo (nivolumab), which is used across several tumor indications and remains one of the company’s key global growth drivers according to its corporate materials.Bristol-Myers Squibb product information on Opdivo
Where the shares trade today
The Bristol-Myers Squibb shares (US1078421011) trade on 2026-06-25 at around 55 dollars on the NYSE in US trading, in a corridor that has recently spanned roughly 54 to 57 dollars based on third-party market data.
Key data on the Bristol-Myers Squibb shares
- Company: Bristol-Myers Squibb Company
- ISIN: US1078421011
- WKN: 850501
- Ticker: BMY
- Trading venue: NYSE
- Price (as of 2026-06-25, 16:06): 55.00 USD
- Market cap: approximately 112 billion USD (as of 2026-06-25)
- Sector / industry: Health Care / Pharmaceuticals
- Index membership: S&P 500
- Next earnings date: 2026-07-25 (company guidance and market calendars)
Disclaimer: This article is for informational purposes only and does not constitute investment advice, a recommendation, or a solicitation to buy or sell any security. All data are based on sources believed to be reliable at the time of publication but may change without notice. Readers should conduct their own research or consult a qualified financial advisor before making investment decisions.
